Quarterly Result10 Aug 2025, 10:01 pm
SMS Pharmaceuticals Reports 24% YoY Increase in PAT for Q1 FY26
AI Summary
SMS Pharmaceuticals Limited (SMS Pharma) has announced its unaudited financial results for the quarter ended June 30, 2025. The company reported a 19% YoY increase in revenue to INR 196.05 crore, driven by strong demand for key APIs. Gross margins grew by 12% YoY to reach INR 65.35 crore. EBITDA margin was stable at 20%, improving 364 bps sequentially but down 30 bps YoY. EBITDA for Q1FY26 rose by 17% YoY to reach INR 239.37 crore. PAT was INR 220.50 crore, up 24% YoY. The company has successfully commissioned its backward integration project and is now scaling up production. SMS Pharma is on track to deliver 20% revenue growth in FY26 with EBITDA margins of 20%.
Key Highlights
- Revenue from operations in Q1FY26 was INR 196.05 crore, up 19% YoY
- Gross margins grew by 12% YoY to reach INR 65.35 crore
- EBITDA for Q1FY26 rose by 17% YoY to reach INR 239.37 crore
- PAT was INR 220.50 crore, up 24% YoY
- Successfully commissioned backward integration project